Haldol decanoate im administration

The influence of renal impairment on the pharmacokinetics of haloperidol has not been evaluated. About one-third of a haloperidol dose is excreted in urine, mostly as metabolites. Less than 3% of administered haloperidol is eliminated unchanged in the urine. Haloperidol metabolites are not considered to make a significant contribution to its activity, although for the reduced metabolite of haloperidol, back-conversion to haloperidol cannot be fully ruled out. Even though impairment of renal function is not expected to affect haloperidol elimination to a clinically relevant extent, caution is advised in patients with renal impairment, and especially those with severe impairment, due to the long half-life of haloperidol and its reduced metabolite, and the possibility of accumulation (see section ).

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

SIMPONI ARIA® (golimumab) is a prescription medicine. SIMPONI ARIA® can lower your ability to fight infections. There are reports of serious infections caused by bacteria, fungi, or viruses that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor will test you for TB before starting SIMPONI ARIA® and will closely monitor you for signs of TB during treatment. Tell your doctor if you have been in close contact with people with TB. Tell your doctor if you have been in a region (such as the Ohio and Mississippi River Valleys and the Southwest) where certain fungal infections like histoplasmosis or coccidioidomycosis are common.

Tell your doctor if you are or plan to become pregnant, are breastfeeding or plan to breastfeed. INVOKAMET® may harm your unborn baby. If you become pregnant while taking INVOKAMET®, tell your doctor as soon as possible. If you are a premenopausal woman (before the "change of life"), who does not have periods regularly or at all, INVOKAMET® may increase your chance of becoming pregnant. Talk to your doctor about birth control choices while taking INVOKAMET®, if not planning to become pregnant. Tell your doctor right away if you become pregnant. INVOKAMET® may pass into your breast milk and harm your baby. Do not breastfeed while taking INVOKAMET®.

Haldol decanoate im administration

haldol decanoate im administration

Tell your doctor if you are or plan to become pregnant, are breastfeeding or plan to breastfeed. INVOKAMET® may harm your unborn baby. If you become pregnant while taking INVOKAMET®, tell your doctor as soon as possible. If you are a premenopausal woman (before the "change of life"), who does not have periods regularly or at all, INVOKAMET® may increase your chance of becoming pregnant. Talk to your doctor about birth control choices while taking INVOKAMET®, if not planning to become pregnant. Tell your doctor right away if you become pregnant. INVOKAMET® may pass into your breast milk and harm your baby. Do not breastfeed while taking INVOKAMET®.

Media:

haldol decanoate im administrationhaldol decanoate im administrationhaldol decanoate im administrationhaldol decanoate im administrationhaldol decanoate im administration